New Drug That Improves Survival in People with Advanced Brain Cancer Created by Prof. Dr. Ines Batinic-Haberle, Editorial Board Member of Antioxidants

We are pleased to announce that our Editorial Board Member, Prof. Dr. Ines Batinic-Haberle from Duke University School of Medicine, USA, created a new drug called BMX-001, which improved survival and lessened cognitive decline for people with advanced brain cancer (high-grade glioma) enrolled in a phase 2 clinical trial. The drug is also under study in clinical trials for several other cancers. 

BMX-001 mimics the action of an enzyme made naturally by the body called superoxide dismutase, which was discovered in the 1960s by Irwin Fridovich, Ph.D., a Duke biochemist who was internationally renowned as “the father of free radical biology”. 

Free radicals are unstable forms of oxygen that can damage cells. Dr. Fridovich discovered that superoxide dismutase neutralizes free radicals, and thus, it is “the enzyme that we cannot live without”, Prof. Dr. Batinic-Haberle said.

You can learn more about the new drug at the following link: https://medschool.duke.edu/news/drug-born-duke-improves-survival-people-advanced-brain-cancer.

Let us congratulate Prof. Dr. Ines Batinic-Haberle on her success and new achievement.